RxDoctor Payments Data

Harjit Bajaj, MD

Neurology · Baltimore, MDNPI 1811977051

Payments from drug & device makers

$25,389in general payments, 2019–2025

Across 1,396 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Novartis$2K
  • UCB, Inc.$2K
  • Biogen$1K
  • EMD Serono, Inc.$1K
  • plus $14K from 53 others

What the payments were for

  • Food & beverage$25,18099%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)220$2,770
Teva Pharmaceuticals USA, Inc.147$2,582
Novartis155$1,704
UCB, Inc.92$1,552
Biogen64$1,386
EMD Serono, Inc.46$1,079
Eisai Inc.52$1,001
Pfizer41$826
Argenx US, Inc.32$785
Neurelis, Inc.41$768
Johnson & Johnson(2 entities)32$768
Bristol Myers Squibb44$691
Sumitomo Pharma America, Inc.39$611
AstraZeneca24$599
Banner Life Sciences, LLC26$535
Lundbeck LLC17$486
CSL Behring19$468
Acadia Pharmaceuticals Inc18$453
Biohaven Pharmaceuticals, Inc.23$452
Amgen(2 entities)22$446
Tanabe Pharma America, Inc.18$393
Mallinckrodt Hospital Products Inc.15$388
SK Life Science, Inc.12$381
Neurocrine Biosciences, Inc.16$363
Jazz Pharmaceuticals Inc.13$314
Biohaven Pharmaceutical Holding Company Ltd.23$299
Vanda Pharmaceuticals Inc.9$243
Grifols USA, LLC11$241
Avanir Pharmaceuticals, Inc.13$227
Organon1$222
Genentech USA, Inc.9$217
Lilly USA, LLC10$213
Sanofi10$194
Greenwich Biosciences, Inc.9$166
Adamas Pharmaceuticals, Inc.10$163
Catalyst Pharmaceuticals, Inc.6$136
Sunovion Pharmaceuticals Inc.1$125
Amneal Pharmaceuticals LLC5$98
Mallinckrodt Enterprises LLC4$95
Takeda Pharmaceuticals U.S.A., Inc.2$94
Otsuka America Pharmaceutical, Inc.4$92
Arbor Pharmaceuticals, Inc.5$85
Supernus Pharmaceuticals, Inc.5$82
Cycle Pharmaceuticals Inc3$76
Bayer3$59
MDD US Operations, LLC3$55
E.r. Squibb & Sons, L.L.C.3$51
Sanofi-aventis U.S. LLC2$44
Nevro Corp.2$40
Akcea Therapeutics, Inc.2$39
Acorda Therapeutics, Inc2$38
Azurity Pharmaceuticals, Inc.2$37
TG Therapeutics, Inc.2$35
Currax Pharmaceuticals LLC2$30
Kyowa Kirin, Inc.1$21
Alnylam Pharmaceuticals Inc.1$21
Livanova USA, Inc.1$19
Medtronic1$18
Avion Pharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,389 in reported general payments places this provider in the 75th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$241,469
Medicare patients
569
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Plegridy PenPeginterferon Beta-1a13$110,890
AustedoDeutetrabenazine12$90,694
EpidiolexCannabidiol (Cbd)12$85,505
NamzaricMemantine Hcl/Donepezil Hcl44$65,312
FycompaPerampanel29$44,198
AptiomEslicarbazepine Acetate17$38,442
BriviactBrivaracetam14$29,481
Emgality PenGalcanezumab-Gnlm15$10,847
Lacosamide42$9,517
Levetiracetam165$5,882
Carbidopa-Levodopa ErCarbidopa/Levodopa53$4,249
Carbamazepine46$3,413
Divalproex Sodium68$2,650
Phenobarbital63$2,547
Pregabalin39$2,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$2,582$90,69412 claims
AbbVieNamzaric$2,770$65,31244 claims
Eisai Inc.Fycompa$1,001$44,19829 claims
Sunovion Pharmaceuticals Inc.Aptiom$125$38,44217 claims
UCB, Inc.Briviact$1,552$29,48114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →